Skip to content


We engage with academic institutions and works with academic advisors with expertise in the area of the development and pipeline projects.

We have partnerships with:

  • Department of Pharmacology and Personalized Medicine, Maastricht University
  • Department of Psychiatry and Neuropsychology, Maastricht University

We are partners of 2 funded platforms for development of repurposed drugs:

REPO-TRIAL is a €5.5M EU funded platform for developing a computerized (in silico) approach to optimize the efficacy and precision of drug repurposing trials. REPO-TRIAL has received funding from the European Union’s Horizon 2020 Research and Innovation program under grant agreement No. 777111.

REPO4EU is a €23M EU-funded Euro-global platform for mechanism-based drug repurposing –from low precision drug therapy to high precision curative therapy– through real-world data, Artificial Intelligence and every step necessary from lab to phase II clinical. REPO4EU receives funding from the European Union’s Horizon Europe research and innovation program under grant agreement No. 101057619.

We are currently seeking new business opportunities that span repurposed medicine.


  • Marty Groen in ‘t Woud, Chief Business Officer